A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2014
Price : $35 *
At a glance
- Drugs LY 03005 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Acronyms LY03005SAD
- Sponsors Luye Pharma Group
- 09 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Aug 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 24 Feb 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.